Paradigm Biopharmaceuticals Ltd's (ASX:PAR) CEO Paul Rennie speaks to Proactive's Andrew Scott after announcing they've initiated a Phase II clinical trial of subcutaneous injectable Pentosan Polysulphate Sodium (iPPS), in patients with the ultra-rare orphan disease Mucopolysaccharidosis Type 1 (MPS-1). The Phase II trial will be Paradigm’s first in MPS-I patients and will investigate treatment in a population, including pediatric patients.
viewParadigm Biopharmaceuticals Ltd
Paradigm Biopharma CEO 'buoyed, enthusiastic and proud' as it begins dosing in Phase II MPS trial
Quick facts: Paradigm Biopharmaceuticals Ltd
Price: 2.48 AUD
ASX:PAR
Market: ASX
Market Cap: $560.12 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Paradigm Biopharmaceuticals Ltd named herein, including the promotion by the Company of Paradigm Biopharmaceuticals Ltd in any Content on the...
FOR OUR FULL DISCLAIMER CLICK HEREDeep dive
Paradigm Biopharmaceuticals lays out roadmap for the future at JP...
Most read
Tiziana Life Sciences hires scientist with track record of successfully...
2 days, 10 hours ago
Coronavirus: Synairgen starts final phase of treatment trials days after UK...
2 days, 2 hours ago
Open Orphan doses first volunteer with next-generation coronavirus vaccine
4 days, 9 hours ago
Tonix Pharmaceuticals forms second research collaboration with Massachusetts...
3 days, 22 hours ago
